Sana Biotechnology’s (SANA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a report released on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock.

A number of other brokerages have also recently issued reports on SANA. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Citigroup boosted their price target on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, August 9th.

Sana Biotechnology Trading Up 9.0 %

Shares of NASDAQ:SANA opened at $2.78 on Wednesday. The stock has a fifty day simple moving average of $3.51 and a two-hundred day simple moving average of $5.14. The stock has a market capitalization of $620.69 million, a price-to-earnings ratio of -1.99 and a beta of 1.44. Sana Biotechnology has a 12-month low of $2.29 and a 12-month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. As a group, equities research analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Insider Transactions at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 31.10% of the company’s stock.

Institutional Trading of Sana Biotechnology

Several large investors have recently modified their holdings of SANA. Vanguard Group Inc. grew its holdings in shares of Sana Biotechnology by 24.1% in the first quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after acquiring an additional 2,358,089 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Sana Biotechnology by 2.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock valued at $36,956,000 after purchasing an additional 101,434 shares during the period. Clarius Group LLC grew its holdings in Sana Biotechnology by 34.9% during the second quarter. Clarius Group LLC now owns 63,184 shares of the company’s stock valued at $345,000 after purchasing an additional 16,359 shares during the period. Bank of New York Mellon Corp grew its holdings in Sana Biotechnology by 26.5% during the second quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock valued at $2,357,000 after purchasing an additional 90,423 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Sana Biotechnology by 20.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock valued at $163,000 after purchasing an additional 5,090 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.